Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
Identifieur interne : 006315 ( Main/Exploration ); précédent : 006314; suivant : 006316Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
Auteurs :Source :
- Lancet [ 0140-6736 ] ; 2009.
Abstract
Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial cancer. Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a therapeutic procedure; however, randomised trials need to be done to assess therapeutic efficacy. The ASTEC surgical trial investigated whether pelvic lymphadenectomy could improve survival of women with endometrial cancer.
From 85 centres in four countries, 1408 women with histologically proven endometrial carcinoma thought preoperatively to be confined to the corpus were randomly allocated by a minimisation method to standard surgery (hysterectomy and BSO, peritoneal washings, and palpation of para-aortic nodes; n=704) or standard surgery plus lymphadenectomy (n=704). The primary outcome measure was overall survival. To control for postsurgical treatment, women with early-stage disease at intermediate or high risk of recurrence were randomised (independent of lymph-node status) into the ASTEC radiotherapy trial. Analysis was by intention to treat. This study is registered, number ISRCTN 16571884.
After a median follow-up of 37 months (IQR 24–58), 191 women (88 standard surgery group, 103 lymphadenectomy group) had died, with a hazard ratio (HR) of 1·16 (95% CI 0·87–1·54; p=0·31) in favour of standard surgery and an absolute difference in 5-year overall survival of 1% (95% CI −4 to 6). 251 women died or had recurrent disease (107 standard surgery group, 144 lymphadenectomy group), with an HR of 1·35 (1·06–1·73; p=0·017) in favour of standard surgery and an absolute difference in 5-year recurrence-free survival of 6% (1–12). With adjustment for baseline characteristics and pathology details, the HR for overall survival was 1·04 (0·74–1·45; p=0·83) and for recurrence-free survival was 1·25 (0·93–1·66; p=0·14).
Our results show no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer. Pelvic lymphadenectomy cannot be recommended as routine procedure for therapeutic purposes outside of clinical trials.
Medical Research Council and National Cancer Research Network.
Url:
DOI: 10.1016/S0140-6736(08)61766-3
PubMed: 19070889
PubMed Central: 2646126
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 004181
- to stream Pmc, to step Curation: 004180
- to stream Pmc, to step Checkpoint: 003756
- to stream Ncbi, to step Merge: 003112
- to stream Ncbi, to step Curation: 003112
- to stream Ncbi, to step Checkpoint: 003112
- to stream Main, to step Merge: 006391
- to stream Main, to step Curation: 006315
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study</title></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19070889</idno><idno type="pmc">2646126</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646126</idno><idno type="RBID">PMC:2646126</idno><idno type="doi">10.1016/S0140-6736(08)61766-3</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">004181</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004181</idno><idno type="wicri:Area/Pmc/Curation">004180</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004180</idno><idno type="wicri:Area/Pmc/Checkpoint">003756</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003756</idno><idno type="wicri:Area/Ncbi/Merge">003112</idno><idno type="wicri:Area/Ncbi/Curation">003112</idno><idno type="wicri:Area/Ncbi/Checkpoint">003112</idno><idno type="wicri:Area/Main/Merge">006391</idno><idno type="wicri:Area/Main/Curation">006315</idno><idno type="wicri:Area/Main/Exploration">006315</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study</title></analytic><series><title level="j">Lancet</title><idno type="ISSN">0140-6736</idno><idno type="eISSN">1474-547X</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><sec><title>Background</title><p>Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial cancer. Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a therapeutic procedure; however, randomised trials need to be done to assess therapeutic efficacy. The ASTEC surgical trial investigated whether pelvic lymphadenectomy could improve survival of women with endometrial cancer.</p></sec><sec><title>Methods</title><p>From 85 centres in four countries, 1408 women with histologically proven endometrial carcinoma thought preoperatively to be confined to the corpus were randomly allocated by a minimisation method to standard surgery (hysterectomy and BSO, peritoneal washings, and palpation of para-aortic nodes; n=704) or standard surgery plus lymphadenectomy (n=704). The primary outcome measure was overall survival. To control for postsurgical treatment, women with early-stage disease at intermediate or high risk of recurrence were randomised (independent of lymph-node status) into the ASTEC radiotherapy trial. Analysis was by intention to treat. This study is registered, number ISRCTN 16571884.</p></sec><sec><title>Findings</title><p>After a median follow-up of 37 months (IQR 24–58), 191 women (88 standard surgery group, 103 lymphadenectomy group) had died, with a hazard ratio (HR) of 1·16 (95% CI 0·87–1·54; p=0·31) in favour of standard surgery and an absolute difference in 5-year overall survival of 1% (95% CI −4 to 6). 251 women died or had recurrent disease (107 standard surgery group, 144 lymphadenectomy group), with an HR of 1·35 (1·06–1·73; p=0·017) in favour of standard surgery and an absolute difference in 5-year recurrence-free survival of 6% (1–12). With adjustment for baseline characteristics and pathology details, the HR for overall survival was 1·04 (0·74–1·45; p=0·83) and for recurrence-free survival was 1·25 (0·93–1·66; p=0·14).</p></sec><sec><title>Interpretation</title><p>Our results show no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer. Pelvic lymphadenectomy cannot be recommended as routine procedure for therapeutic purposes outside of clinical trials.</p></sec><sec><title>Funding</title><p>Medical Research Council and National Cancer Research Network.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Boyle, P" uniqKey="Boyle P">P Boyle</name></author><author><name sortKey="Leon, Me" uniqKey="Leon M">ME Leon</name></author><author><name sortKey="Maisonneuve, P" uniqKey="Maisonneuve P">P Maisonneuve</name></author><author><name sortKey="Autier, P" uniqKey="Autier P">P Autier</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Sant, M" uniqKey="Sant M">M Sant</name></author><author><name sortKey="Aareleid, T" uniqKey="Aareleid T">T Aareleid</name></author><author><name sortKey="Berrino, F" uniqKey="Berrino F">F Berrino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boronow, Rc" uniqKey="Boronow R">RC Boronow</name></author><author><name sortKey="Morrow, Cp" uniqKey="Morrow C">CP Morrow</name></author><author><name sortKey="Creasman, Wt" uniqKey="Creasman W">WT Creasman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Creasman, Wt" uniqKey="Creasman W">WT Creasman</name></author><author><name sortKey="Morrow, Cp" uniqKey="Morrow C">CP Morrow</name></author><author><name sortKey="Bundy, Bn" uniqKey="Bundy B">BN Bundy</name></author><author><name sortKey="Homesley, Hd" uniqKey="Homesley H">HD Homesley</name></author><author><name sortKey="Graham, Je" uniqKey="Graham J">JE Graham</name></author><author><name sortKey="Heller, Pb" uniqKey="Heller P">PB Heller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kong, A" uniqKey="Kong A">A Kong</name></author><author><name sortKey="Simera, I" uniqKey="Simera I">I Simera</name></author><author><name sortKey="Collingwood, M" uniqKey="Collingwood M">M Collingwood</name></author><author><name sortKey="Williams, C" uniqKey="Williams C">C Williams</name></author><author><name sortKey="Kitchener, H" uniqKey="Kitchener H">H Kitchener</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Shepherd, Jh" uniqKey="Shepherd J">JH Shepherd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kilgore, Lc" uniqKey="Kilgore L">LC Kilgore</name></author><author><name sortKey="Partridge, Ee" uniqKey="Partridge E">EE Partridge</name></author><author><name sortKey="Alvarez, Rd" uniqKey="Alvarez R">RD Alvarez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morrow, Cp" uniqKey="Morrow C">CP Morrow</name></author><author><name sortKey="Bundy, Bn" uniqKey="Bundy B">BN Bundy</name></author><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trimble, El" uniqKey="Trimble E">EL Trimble</name></author><author><name sortKey="Kosary, C" uniqKey="Kosary C">C Kosary</name></author><author><name sortKey="Park, Rc" uniqKey="Park R">RC Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wells, M" uniqKey="Wells M">M Wells</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lefebvre, C" uniqKey="Lefebvre C">C Lefebvre</name></author><author><name sortKey="Clarke, M" uniqKey="Clarke M">M Clarke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Panici, Pb" uniqKey="Panici P">PB Panici</name></author><author><name sortKey="Basile, S" uniqKey="Basile S">S Basile</name></author><author><name sortKey="Maneschi, F" uniqKey="Maneschi F">F Maneschi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cragun, Jm" uniqKey="Cragun J">JM Cragun</name></author><author><name sortKey="Havrilesky, Lj" uniqKey="Havrilesky L">LJ Havrilesky</name></author><author><name sortKey="Calingaert, B" uniqKey="Calingaert B">B Calingaert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fanning, J" uniqKey="Fanning J">J Fanning</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mohan, Ds" uniqKey="Mohan D">DS Mohan</name></author><author><name sortKey="Samuels, Ma" uniqKey="Samuels M">MA Samuels</name></author><author><name sortKey="Selim, Ma" uniqKey="Selim M">MA Selim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lutman, Cv" uniqKey="Lutman C">CV Lutman</name></author><author><name sortKey="Havrilesky, Lj" uniqKey="Havrilesky L">LJ Havrilesky</name></author><author><name sortKey="Cragun, Jm" uniqKey="Cragun J">JM Cragun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jk" uniqKey="Chan J">JK Chan</name></author><author><name sortKey="Cheung, Mk" uniqKey="Cheung M">MK Cheung</name></author><author><name sortKey="Huh, Wk" uniqKey="Huh W">WK Huh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keys, Hm" uniqKey="Keys H">HM Keys</name></author><author><name sortKey="Roberts, Ja" uniqKey="Roberts J">JA Roberts</name></author><author><name sortKey="Brunetto, Vl" uniqKey="Brunetto V">VL Brunetto</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:2646126
|texte= Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19070889" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |